Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.

MLA

Visco, Denise M., et al. “Matching-Adjusted Indirect Comparison of Phase 3 Clinical Trial Outcomes: OC-01 (Varenicline Solution) Nasal Spray and Cyclosporine a 0.05% Ophthalmic Emulsion for the Treatment of Dry Eye Disease.” Journal of Managed Care & Specialty Pharmacy, vol. 28, no. 8, Aug. 2022, pp. 892–902. EBSCOhost, https://doi.org/10.18553/jmcp.2022.22005.

APA

Visco, D. M., Hendrix, L. H., Sun, L., Tam, I., Macsai, M., & Gibson, A. A. (2022). Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease. Journal of Managed Care & Specialty Pharmacy, 28(8), 892–902. https://doi.org/10.18553/jmcp.2022.22005

Chicago

Visco, Denise M, Laura H Hendrix, Lucille Sun, Iris Tam, Marian Macsai, and Andrea A Gibson. 2022. “Matching-Adjusted Indirect Comparison of Phase 3 Clinical Trial Outcomes: OC-01 (Varenicline Solution) Nasal Spray and Cyclosporine a 0.05% Ophthalmic Emulsion for the Treatment of Dry Eye Disease.” Journal of Managed Care & Specialty Pharmacy 28 (8): 892–902. doi:10.18553/jmcp.2022.22005.